Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Puntos clave

• Overall survival significantly improved with brentuximab vedotin plus chemotherapy, marking a positive impact on treatment outcomes.
• Five-year follow-up revealed favorable results for younger patients receiving this combined therapy over chemotherapy alone.
• Subgroup analysis focused on various demographics and risk factors to assess treatment efficacy and safety parameters.
• Findings highlight the effectiveness of brentuximab vedotin in enhancing survival prospects for anaplastic large cell lymphoma patients.